



Parkinson’s disease (PD) is 
one of the most common neu-
rodegenerative diseases in the 
elderly. Motor symptoms are 
primarily due to significant 
dopamine depletion caused by 
degeneration of dopaminergic 
neurons in the compact sub-
stantia nigra [1].
Apoptosis is the predomi-
nant mode of neuronal death 
in many neurodegenerative dis-
eases, including PD. While the 
pathogenetic processes in PD 
have not been fully studied, con-
vergent mechanisms lead to the 
death of neurons due to apop-
tosis, which makes the path of 
apoptosis an interesting poten-
tial therapeutic target [2]. Cell 
death by apoptosis is observed 
in cell culture models of animals 
with PD, as well as in the ni-
grostriatal regions of the brain 
of patients with PD at autop-
sy [3]. Elucidation of the main 
triggers of the apoptotic process 
in PD can lead to a better un-
derstanding of the sequence of 
events that lead to programmed 
cell death.
The aim of the study. To 
study apoptotic processes and 
their role in the formation of 
premature dopaminergic neu-
rodegeneration, to identify key 
biomarkers for early diagnosis 
and implementation of preven-
tive programs towards stopping 
the progression of PD in the early 
stages, to develop new treatment 
regimens with a specific neuro-
protective effect on the dopami-
nergic system.
2. Materials and methods
All experiments were conducted during 2018–2020 on 
the basis of the Training Medical and Laboratory Centre of 
Zaporizhia State Medical University, certified by the Ministry 
of Health of Ukraine (certificate No. 039/14). The study was 
carried out on 90 Wistar rats at the age of 6 months weighing 
220–290 grams. Parkinsonism was induced by the administra-
tion of the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine) to experimental rats. The intact group received 
a single intraperitoneal saline solution of 1 ml per 100 g of body 
weight, and the control group, after administration of MPTP, 
received a single intraperitoneal saline solution at the same 
dosage.
The study was conducted in accordance with Directive 
2010/63EU of the European Parliament and of the Council 
of 22 September 2010 on the protection of animals used for 
scientific purposes, as well as with the national “Common 
Ethical Principles for Animal Experiments” (Ukraine, 2001) 
and the guidelines set out in in 
“Basic principles of studying the 
toxicity of potential pharmaco-
logical drugs” (State Enterprise 
«Ukrainian Pharmaceutical Qua- 
lity Institute», K., 2000). The expe- 
riment was approved by the Com-
mission on Bioethics of Zapori- 
zhia State Medical University.
The verification for the strat-
egy of rational therapy in PD 
was based on studying the ac-
tivity of drugs in groups of ani-
mals: I – Intact (passive control); 
II – animals with experimental 
Parkinson’s disease (PD, active 
control); III – PD+Amantadine 
(AM) IV – PD+AM+Cerebrocu- 
rin; V – PD+AM+Pramistar; VI – 
PD+AM+Gliatilin; VII – PD+ 
AM+Noofen; VIII – PD+AM+ 
Pronoran; IX – PD+AM+Mela-
tonin.
The concentration in the cy-
toplasmic fraction of the brain of 
HSP70 protein was determined 
by Western blot analysis. To an-
alyze the expression of the genes 
HSP70, HIF-1α, HIF-3α and 
bcl-2, we used the method of Re-
verse transcription polymerase 
chain reaction (RT-PCR). The ob-
ject of the study was brain homog-
enate. Determination of caspase-3 
was performed by ELISA – a sol-
id-phase enzyme-linked immuno-
sorbent assay based on the prin-
ciple of “sandwich” and based on 
the specific binding of antibodies 
to antigen, with one of the com-
ponents conjugated to the enzyme.
Data are presented as mean 
and standard error of the mean. 
The statistical significance of in-
tergroup differences was assessed 
using the Mann-Whitney meth-
od. Statistical analysis was performed using the program “Sta-
tistica 6.1” (StatSoft Inc., USA, serial No. RGXR412D674002F-
WC7). For all types of analysis, differences at a significance 
level of less than 0.05 were considered statistically significant.
3. Results
In the control group of our study in rats with PD in con-
ditions of increased reactions of oxidative, nitrosative stress 
and deficiency of energy resources in brain tissues, there is a 
decrease in HIF1a synthesis compared to the intact group of 
animals by 25.72 % and HIF3a – by 74.12 %. These processes 
are associated with the activation of the ubiquitin-indepen-
dent degradation pathway of oxidatively modified HIF-1α and 
HIF3a, and the suppression of its synthesis during translation. 
The administration of amantadine, as well as its combination 
with cerebrocurin, gliatilin, noophen, pronoran and pramistar 
in PD conditions had almost no effect on the level of HIF1a 
mRNA expression compared to the control group, except for 
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the melatonin group, where there is a statistically significant in-
crease in expression of this gene (6.10 %). The increase in HIF3a 
mRNA expression compared to the control group in the aman-
tadine group was 70.76 %, in the cerebrocurin group – 82.35 % 
(p≤0.05), pramistar – 67.72 %, gliatilin – 79.44 % (p≤0.05), 
noophen – 67.47 %, pronoran – 81.65 %, melatonin – 82.92 %.
The neuroprotective effects of our drugs are associated with 
the normalization of endogenous neuroprotection HSP70 on 
the background of activation of gene expression of antioxidant 
enzymes compared with the control group: in the group of 
amantadine – by 31.86 % (p≤0.05), in the group of cerebrocu- 
rin – 15.08 % (p≤0.05), pramistar – 30.44 %, gliatilin – 16.26 %, 
noophen – 23.77 %, pronoran – 23.96 % (p≤0.05), melatonin – 
34.66 % (p≤0.05).
In the brain of control rats, the PD model showed an in-
crease in the expression of c-fos (c-fos-positive neuronal cells) 
by almost 52.75 % relative to the intact group of animals, which 
reflects the progressive activation of apoptotic processes and 
the death of dopamine-producing neurons. The expression of 
c-fos mRNA in the control group increased by 44.53 % relative 
to intact. In our study, the following dynamics of Fos-positive 
neurons was noted: the appointment of amantadine reduced 
expression by 7.25 % (p≤0.05), in the group of cerebrocurin – 
by 31.24 % (p≤0.05), pramistar – 19.68 %, gliatilin – 35.85 %, 
noophen – 26.70 %, pronoran – 21.34 % (p≤0.05), melatonin – 
37.84 % (p≤0.05). Similar statistically significant dynamics was 
observed in the study of c-fos mRNA expression against the 
background of therapeutic effects in rats with PD: decreased ex-
pression of c-fos mRNA in all groups, but especially pronounced 
depression of apoptotic activity of this early response gene was 
in drugs cerebrocurin, gliatilin, pronoran and, especially, mela-
tonin, and the values approached the group of intact.
In the control group on the background of PD there was a 
decrease in the density of bcl-2-positive neurons relative to in-
tact by 27.85 %, and the expression of bcl-2 mRNA decreased by 
26.09 %. After amantadine treatment of rats with PD, the den-
sity of bcl-2-positive neurons increased compared to the control 
by 10.18 % (p≤0.05), in the group of cerebrocurin – by 23.71 % 
(p≤0.05), pramistar – 17.54 %, gliatilin – 21.71 % (p≤0.05), 
noophen – 18.60 %, pronoran – 19.73 %, melatonin – 26.13 %. 
Simultaneously, there was an increase in the expression of bcl-2 
mRNA in all experimental groups compared with the control, 
especially with the appointment of melatonin, cerebrocurin, 
gliatilin and pronoran within statistical significance.
A sign of activation of apoptosis of neuronal cells under the 
conditions of PD was also an increase in the activity of caspase-3 
in the control group by 50.29 % relative to the control group. 
The therapeutic effect of the amantadine led to a decrease in 
this marker by only 6.01 % (p≤0.05), while the combination of 
amantadine with cerebrocurin reduced caspase-3 by 38.25 %, 
with gliatilin – by 40.78 % (p≤0.05), with noophen – by 20.58 %, 
with pronoran – by 28.35 %, and with melatonin – by 45.05 %.
4. Discussion
Cerebrocurin has a complex neuroprotective effect due 
to its ability to stabilize the functional state of mitochondria 
and limit the development of mitochondrial dysfunction [4]; 
to prevent the formation of energy deficit; block the develop-
ment of lactic acidosis against the background of activation of 
compensatory mitochondrial-cytosolic shunts of energy prod-
ucts, especially malate-aspartate; reduce the manifestations of 
oxidative and nitrosative stresses; modulate the expression of 
all isoforms of NOS, as well as HIF and HSP proteins; increase 
the activity of enzymes of the antioxidant and thiol-disulfide 
systems; morphologically stabilize neuronal and glial cells with 
parallel activation of RNA synthesis in them, as well as to re-
store the morphological ultrastructure of mitochondria; affect 
the processes of apoptosis/necrosis and due to the regulatory 
effect on the expression of c-fos. Cerebrocurin increases HSP70 
expression by activating NFkB [5]. Melatonin in PD increases 
the level of HSP70 due to the activation of melatonin receptors 
MT1 and MT2 [6]. In addition, the unique structure of the 
melatonin molecule makes it an effective scavenger of ROS/AFA 
and prevents total damage to polypeptide bonds, inactivation of 
enzyme systems, antioxidant units of endogenous protection, 
including HSP70. Melatonin is also able to have a cytoprotective 
effect by maintaining the activity of glutathione peroxidase, 
Cu, Zn- and Mn-superoxide dismutase, and γ-glutamylcysteine 
ligase [7]. However, the ability of the drug to inhibit a number 
of prooxidant enzymes, such as lipoxygenase and NO syn-
thase, which under conditions of PD reduces the production of 
ROS [8]. The positive effect of melatonin on energy metabolism 
is due to its ability to prevent damage to aconitate hydrolase 
and thus maintain the Krebs cycle at the citrate-isocitrate stage. 
Pramistar restores thiol-disulfide balance in the brain with PD, 
limits the expression of iNOS [9]. By increasing the level of re-
duced glutathione, pramistar is able to increase the expression 
of HSP70. Gliatilin increases synaptogenesis in cholinergic 
structures, has a mitoprotective effect, increases the level of 
intramitochondrial glutathione and is able to increase the level 
of HSP70 [10].
Thus, although apoptosis is the last step in the pathogenetic 
pathway in PD, it remains to be seen whether inhibition of apop-
tosis in PD can be effective and safe, and careful evaluation of 
the literature and experimental findings is necessary.
Study limitations. There may be some possible limitations 
in this study: the financial resources, deficiency prior research 
works/surveys on this issue and the absence of the dose-depen-
dent treatment effect research.
Prospects for further research. Prospects for further re-
search are to study the features of changing the behavioral 
reactions and cognitive-mnestic functions of rats under experi-
mental Parkinson’s disease and the prospects of development of 
a strategy of pharmacological correction. 
5. Conclusions
The data obtained indicate that neuroprotective therapy of 
PD with drugs such as melatonin, cerebrocurin, pronoran and 
gliatilin in combination with amantadine leads to an increase 
in the expression of the HIF-1α, HIF-3α, and HSP70 genes, 
and can also serve as a molecular marker for the activation of 
endogenous neuroprotection mechanisms under the conditions 
of an experimental PD.
The study of the mechanisms of programmed neuronal 
death by apoptosis in PD under conditions of oxidative stress 
and pharmacological correction of the mechanisms of apoptosis 
realization is a pathogenetically justified target of therapy for 
socially significant diseases. We offer c-fos and bcl-2 proteins as 
well as effector caspase-3 as markers of apoptosis.
We have experimentally demonstrated a new target of neu-
roprotection in PD conditions – apoptosis of dopamine-pro-
ducing neurons and substantiated modulators of this pro- 
cess – drugs for combined therapy with amantadine (melatonin, 
cerebrocurin, pronoran and gliatilin) as promising drugs for the 
treatment of PD.
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